51 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
discussions to partner with major pharma / biotech companies with a global reach. XORTX will also increase financial and healthcare conference participation … the business of the Company. The Company is subject to the risks of companies operating in the medical and healthcare business. The market in which
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
.
A variety of external factors could also impact our ability to successful commercialize our products. Healthcare legislation and regulations could alter … approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.
Healthcare
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
companies with a global reach. XORTX will also increase financial and healthcare conference participation to further strengthen and expand its investor … with such changes may adversely affect the business of the Company. The Company is subject to the risks of companies operating in the medical and healthcare business
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
discussions to partner with major pharma / biotech companies with a global reach. XORTX will also increase financial and healthcare conference participation … the business of the Company. The Company is subject to the risks of companies operating in the medical and healthcare business. The market in which
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:11pm
.
A variety of external factors could also impact our ability to successful commercialize our products. Healthcare legislation and regulations could alter … approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.
Healthcare
424B3
jbrwctn
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.2
4astblgw d4
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-99.1
hzt0m iftx79kq
22 Apr 24
XORTX Announces Publication of Key Research in ADPKD
7:00am
6-K
EX-99.1
dbys85lposb2hoh32
8 Apr 24
XORTX Announces Participation in Spring 2024 Investor Conferences
7:00am
424B5
gglzw6
29 Nov 23
Prospectus supplement for primary offering
9:57pm
6-K
EX-99.2
14w7 qdhozew9ckyf1
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
424B3
4a1835
25 Aug 23
Prospectus supplement
6:00am
424B3
srajw9311tla4
25 Aug 23
Prospectus supplement
6:00am
6-K
EX-99.2
cgss9d0iif vagv9aj0
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
424B3
35a2disoiyotlmk
14 Aug 23
Prospectus supplement
4:42pm
424B3
cgjoo 8zo
14 Aug 23
Prospectus supplement
4:40pm
POS AM
2ha2a
4 Aug 23
Prospectus update (post-effective amendment)
4:08pm
POS AM
skwgt4ff135 d0
4 Aug 23
Prospectus update (post-effective amendment)
4:05pm